Chronic concomitant treatment with strong CYPA inducers is not allowed; patients must discontinue the drug  days prior to the start of study treatment
Concomitant medications\r\n* Chronic concomitant treatment with strong CYPA inducers or CYPA inhibitors is not allowed; patients must discontinue the drug at least  days prior to study registration\r\n* Chronic concomitant treatment with CYPA substrate is not allowed; patients must discontinue the drug at least  days prior to study registration
Inclusion criteria:\n\n        Parts A, B, C and D:\n\n          -  Patients must be postmenopausal women\n\n          -  Histological diagnosis of breast adenocarcinoma\n\n          -  Locally advanced or metastatic disease\n\n          -  Measurable disease\n\n          -  Previously treated for advanced disease\n\n          -  Either primary tumor or any metastatic site to be positive for Estrogen Receptors\n             (ER+) and negative for human epidermal growth factor receptor  (HER-) by\n             immunohistochemistry (IHC)\n\n        Exclusion criteria:\n\n          -  Medical history or ongoing gastrointestinal disorders that could affect absorption of\n             SAR and/or palbociclib (including difficulties with swallowing capsules)\n\n          -  Patient with any other cancer (except for adequately treated basal cell or squamous\n             cell skin cancer, in situ cervical cancer or any other cancer from which the patient\n             has been disease free for > years)\n\n          -  Patients with known brain metastases and endometrial disorders\n\n          -  Treatment with anticancer agents (including investigational drugs) less than  weeks\n             before first study treatment starts (less than  weeks if the anticancer agents were\n             antibodies)\n\n          -  Prior treatment with another selective ER down-regulator (SERD) (except fulvestrant)\n\n          -  Inadequate hematological and biochemical lab tests\n\n          -  Patients with Gilbert disease\n\n          -  Treatment with human immunodeficiency virus (HIV)-antiviral, antifungal and\n             antioxidant agents less than  weeks before study treatment starts\n\n          -  Treatment with strong and moderate CYPA inducers/inhibitors within  weeks before\n             first study treatment\n\n        Part A only:\n\n        Patients with liver metastases only\n\n        Parts C and D only:\n\n          -  Prior therapy with any selective cyclin-dependent kinase (CDK) / inhibitor\n\n          -  Treatment with strong and moderate CYPA inducers or strong CYPA inhibitors within \n             weeks before first study treatment starts\n\n          -  Medical conditions requiring concomitant medications with that are metabolized by\n             CYPA\n\n        The above information is not intended to contain all considerations relevant to a patient's\n        potential participation in a clinical trial.
Current use or anticipated need for food or medications that are known strong CYPA inhibitors/inducers, including their administration within -days prior to the first gedatolisib (PF-) or palbociclib dose and during study treatment
Strong P-gp inhibitors or inducers. Subjects who are taking such medications but who are otherwise eligible may be enrolled if they discontinue the medication ? week before dosing and remain off that medication through the end of PK sampling after the administration of the second study treatment
Patients who are currently receiving treatment with drugs known to be strong inhibitors or inducers of isoenzyme CYPA including herbal medications; Note: if a medication is incorrectly documented as prohibited in this protocol, documentation from the site pharmacist to the contrary will be acceptable for the purposes of registration
Patients may not be currently receiving strong inhibitors of CYPA, and may not have received these medications within  week prior to study entry; these include:
Treatment with strong CYPA inducers within  days prior to the first dose of study treatment of RO/venetoclax.
Administration of strong/potent cytochrome PA (CYPA) inhibitors or inducers within  days prior to the first dose of study treatment and while on treatment with alectinib
Patient receiving treatment with medications that either strong inducers or inhibitors of CYPC or CYPA/, or patients receiving medication that prohibits proton pump inhibitors and that cannot be discontinued at least  week prior to start of treatment and for the duration of the study.
Use of medications that are known to be strong inhibitors or inducers of CYPA/ that cannot be discontinued at least  week prior to start of treatment with LDK and for the duration of the study
Use of medications that are mainly metabolized by CYPA/ or CYPC that cannot be discontinued at least  week prior to start of treatment with LDK and for the duration of the study.
Receiving medications that meet one of the following criteria and that cannot be discontinued at least  week prior to start of treatment with ceritinib and for the duration of participation:\r\n* Medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes\r\n* Strong inhibitors or strong inducers of CYPA/, and medications with a low therapeutic index that are primarily metabolized by CYPA/, and/or CYPC\r\n* Therapeutic doses of warfarin sodium (coumadin) or any other coumadin-derived anti-coagulant. Anticoagulants not derived from warfarin are allowed (eg, dabigatran, rivaroxaban, apixaban)\r\n* Unstable or increasing doses of corticosteroids in the  days before first dose of study treatment\r\n* Enzyme-inducing anticonvulsive agents
Patients receiving concomitant treatment with strong CYPA inhibitors within  days of start of study therapy (including posaconazole and voriconazole).
STRATUM A: Participants who are receiving known strong inducers and/or strong inhibitors of CYPA/, drugs that have a narrow therapeutic window and are predominantly metabolized through CYPA/, and medications that carry a known risk for QT prolongation must discontinue these drugs at least  days prior to study enrollment
STRATUM B: Participants who are receiving known strong inducers and/or strong inhibitors of CYPA/, drugs that have a narrow therapeutic window and are predominantly metabolized through CYPA/, and medications that carry a known risk for QT prolongation must discontinue there drugs at least  days prior to study enrollment
STRATUM C: Participants who are receiving known strong inducers and/or strong inhibitors of CYPA/, drugs that have a narrow therapeutic window and are predominantly metabolized through CYPA/, and medications that carry a known risk for QT prolongation must discontinue there drugs at least  days prior to study enrollment
Taking known strong cytochrome P (CYP) A inducers, unless they can be transferred to other medications prior to enrolling. For subjects taking AG-, systemic administration of a moderate or strong CYPA inhibitor requires careful monitoring of the heart rate-corrected QT interval (QTc) using Fridericia's formula (QTcF)
Required use of strong inhibitors and inducers of CYP enzymes and transporters.
Patients who are currently receiving treatment with medications that meet one of the following criteria and that cannot be discontinued at least one week prior to the start of treatment with cyclophosphamide and sirolimus:\r\n* Strong inhibitors or inducers of CYPA or P-glycoprotein (P-gp)
Receiving medications that meet one of the following criteria and that cannot be discontinued at least  week prior to the start of treatment with ceritinib and for the duration of participation:\r\n* Medication with a known risk of prolonging the QT interval or inducing torsades de pointes\r\n* Strong inhibitors or strong inducers of CYPA/\r\n* Medications with a low therapeutic index that are primarily metabolized by CYPA/, and/or CYPC\r\n* Therapeutic doses of warfarin sodium (Coumadin) or any other coumadin-derived anticoagulant\r\n* Anticoagulants not derived from warfarin are allowed (eg, dabigatran, rivaroxaban, apixaban)\r\n* Unstable or increasing doses of corticosteroids? If patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms, dose must have been stabilized (or decreasing) for at least  days before first dose of study treatment\r\n* Enzyme-inducing anticonvulsive agents\r\n* Herbal supplements
Patients actively receiving therapy with herbal medicines that are strong CYPA inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry; these herbal medicines may include Echinacea (including Echinacea [E.] purpurea, E. angustifolia and E. pallida), Piperine, Artemisinin, St. Johns Wort, and Ginkgo
Medications known to be clinically significant inhibitors (eg. gemfibrozil) or inducers (eg. rifampin) of CYPC or medications known to be strong cytochrome P (CYP) A inhibitors (eg. ketoconazole) or inducers (eg. rifampin or St. John's Wort). Subjects who are currently taking such medications but who are otherwise eligible may be enrolled if they discontinue the medication  week before dosing and remain off that medication during treatment with Oraxol.
Patients who are receiving drugs that are sensitive substrates of CYP A, A, C, C or D, or strong inhibitors or inducers of all major CYP isozymes that cannot be stopped at least  days or  half-lives (whichever is longer) before starting treatment with ABC and either replaced with another appropriate medication or not given for the duration of the clinical study
Planned ongoing treatment with another drug that may potentially have adverse interactions with brentuximab vedotin; if such a drug has been used, it must be discontinued at least  week prior to initiating study treatment; examples of potential interactions include:\r\n* Coadministration of strong inhibitors of CYPA (eg, ketoconazole, ritonavir, clarithromycin)\r\n* Coadministration of CYPA inducers (eg, rifampin)\r\n* Concomitant treatment with strong inhibitors of P-glycoprotein (P-gp)
Receiving medications that meet one of the following criteria and that cannot be discontinued at least  week prior to the start of treatment with study drug and for the duration of participation:\r\n* Medication with a significant known risk of prolonging the QT interval or inducing Torsades de Pointes\r\n* Strong inhibitors or strong inducers of CYPA/ \r\n* Herbal supplements
Systemic treatment with inducers or strong inhibitors of cytochrome P within four days before enrollment or planned treatment during the time period of the study.
CAPMATINIB EXCLUSION CRITERIA: Patients receiving treatment with medications that meet one of the following criteria and that cannot be discontinued at least  week prior to the start of capmatinib treatment and for the duration of the study:\r\n* Strong and moderate inhibitors of CYPA\r\n* Strong inducers of CYPA\r\n* Proton pump inhibitors (PPI)
CERITINIB EXCLUSION CRITERIA: Receiving medications that meet one of the following criteria and that cannot be discontinued at least  week prior to the start of treatment with study drug and for the duration of participation:\r\n* Medication with a known risk of prolonging the QT interval or inducing torsades de pointes\r\n* Strong inhibitors or strong inducers of CYPA/\r\n* Medications with a low therapeutic index that are primarily metabolized by CYPA/, and/or CYPC\r\n* Therapeutic doses of warfarin sodium (coumadin) or any other coumadin-derived anticoagulant; anticoagulants not derived from warfarin are allowed (e.g., dabigatran, rivaroxaban, apixaban)\r\n* Unstable or increasing doses of corticosteroids\r\n* Enzyme-inducing anticonvulsive agents\r\n* Herbal supplements
Planned ongoing treatment with other drugs thought to potentially have adverse interactions with either of the medications included in the study treatment, for example:\r\n* Alpha -blockers\r\n* Vasodilators, such as nitrates\r\n* Other PDE inhibitors, eg, vardenafil, tadalafil\r\n* Therapeutic anticoagulation with vitamin K antagonists (eg, warfarin), heparins and heparinoids, or direct thrombin inhibitors (DTIs)\r\n** Note: prophylactic low-dose anticoagulation to maintain vascular access devices or low-dose daily aspirin for cardiac health is permitted\r\n* Immunosuppressants such as tacrolimus, leflunomide or tofacitinib, roflumilast, pimecrolimus\r\n** Note: administration of steroids as part of symptom management or for other supportive care purposes is permitted\r\n* STRONG CYPA inhibitors and/or STRONG CYPA inducers; \r\n** Note: if such medications have been used, patients must have discontinued these agents >=  weeks prior to initiating study treatment
Patient must not have received: CYPA inducers within fourteen () days prior to registration and for the duration of the study
Subjects to receive duvelisib: Administration of medications or foods that are strong inhibitors or inducers of cytochrome P (CYP) A within  weeks of starting duvelisib
Strong inhibitors or inducers of cytochrome P A (washout from prior use of such agents before CD must exceed  days)
Chronic concomitant treatment with strong CYPA inducers is not allowed; patients must discontinue the drug  days prior to the start of study treatment
Required ongoing treatment with other drugs thought to potentially have adverse interactions with either of the medications included in the study treatment; if such medications have been used, patients must have discontinued these agents at least  week prior to initiating study treatment; examples include:\r\n* Strong cytochrome P family , subfamily A, polypeptide  (CYPA) inhibitors and/or strong CYPA inducers;\r\n* Strong inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP);\r\n* Simvastatin and other hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (ie, statins)\r\n* Drugs that raise gastric potential of hydrogen (pH) including proton pump inhibitors and histamine- receptor antagonists (hydrogen [H]-blockers); Note: Short-acting antacids, in place of proton pump inhibitors (PPIs) and H-blockers, are permitted\r\n* HDAC inhibitors
The patient is receiving medications that are:\r\n* Drugs which are exclusively or primarily eliminated by cytochrome P- isozyme A (CYPA)\r\n* Drugs which are exclusively or primarily eliminated by UDP-glucuronyl transferase A (UGTA)\r\n* Drugs which are substrates for the drug transporter multidrug resistance protein  (MDR) have a narrow therapeutic window; or which are strong inhibitors of drug transporter MDR\r\n** Patients should have discontinued strong CYPA inhibitors (e.g. ciprofloxacin and fluvoxamine) at least five half-lives before beginning study treatment
Treatment with drugs or herbal supplements known to be strong inhibitors/inducers of cytochrome P A or cytochrome P C within  weeks prior to Day 
Patient is currently receiving any of the prohibited substances that cannot be discontinued  days prior to Cycle  Day : concomitant medications, herbal supplements, and/or fruits and their juices that are known as strong inhibitors or inducers of CYPA/; medications that have a narrow therapeutic window and are predominantly metabolized through CYPA/; systemic corticosteroids ?  weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment; concomitant medications with a known risk to prolong the QT interval and/or known to cause torsades de points that cannot be discontinued or replaced by safe alternative medication.
Has current use (within  days of randomization) or anticipated need for treatment with drugs or foods that are known strong cytochrome P (CYPA/) inhibitors.
The MMAE component of glembatumumab vedotin is primarily metabolized by CYPA. Patients taking strong CYPA inhibitor and inducers are excluded in Phase I (the dose escalation portion), to minimize the effect of these modulators on exposure, tolerability and dose selection.
Treatment with medications that are known to be strong inhibitors or inducers of CYP enzymes.
RPD cohort subjects: contraindications to midazolam, any other midazolam within  days, or any medications or supplements known to be strong CYPA inhibitors within  days or inducers within  days
Recipient of strong/potent cytochrome PA inhibitors or inducers within  days prior to the first dose until the end of study treatment
Patients must not be taking medications that are inducers or inhibitors of CYPA; if previously on such an agent, the patient must be off of it for at least two weeks prior to study treatment
Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P A/ (a one week wash-out period is necessary for patients who are already on  these treatments)
Unable or unwilling to discontinue use of strong inducers and inhibitors of CYP listed for at least  days prior to the first dose of study drug and for the duration of the study; CYPA substrates can be administered, but investigators will need to be aware of possible increased or decreased effectiveness of the non-study drug and this should be recorded in concomitant medications; breast cancer resistance protein (BCRP) and p glycoprotein (PgP) inducers should be used with caution if another alternative drug is not able to be used\r\n* Note: If a medication is incorrectly documented as prohibited in this protocol, documentation from the site pharmacist to the contrary will be acceptable for the purposes of registration
Has plans to use, or is using, any herbal medications/supplements or any medications or foods that are strong inhibitors or inducers of cytochrome P A / ? week prior to the start of study treatment
Patients who previously received CYPA inducers or inhibitors must have discontinued these medications within at least  week prior to study entry and can re-start them  week post-operatively (or earlier if determined to be of clinical benefit, as determined by the treating physician)
Administration of the cytochrome P (CYP)A inducers or inhibitors, as they may induce or inhibit irinotecan or SN metabolism within  days prior to cycle  and throughout study treatment
Patients actively receiving therapy with strong CYPA inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry. See Appendix . for a list of these medications. This list may not be comprehensive.
Patients actively receiving therapy with herbal medicines that are strong CYPA inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to study entry. These herbal medicines may include Echinacea, (including E. purpurea, E. angustifolia and E. pallida), Piperine, Artemisinin, St. John's Wort, and Ginkgo.
Patients may not be currently receiving strong inhibitors of CYPA, and may not have received these medications within  week of entry
Use of known strong or moderate inducers of cytochrome P A (CYPA) in participants receiving ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) with and without dasabuvir (DSV), strong inducers and inhibitors (e.g., gemfibrozil) of cytochrome P C (CYPC) in participants receiving OBV/PTV/r with DSV, medications contraindicated for ritonavir or RBV (for those that receive RBV) within  weeks or  half-lives (if known), whichever is longer, prior to study drug . For medications contraindicated with AbbVie's -direct-acting antiviral agent (-DAA) and -DAA regimen, refer to the recommended prescribing information section of the approved local product labels.
Chronic concomitant treatment with strong CYPA inducers is not allowed; patients must discontinue the drug  days prior to the start of study treatment
Patients receiving treatment with medications that are known to be ) strong inhibitors or inducers of CYPA/; ) CYPC substrate with narrow therapeutic index; ) QT prolonging agents; ) proton pump inhibitors unless these medications can be discontinued at least a week prior to start of treatment.
Patients must discontinue any medication that causes a strong CYPA inhibition  week prior to treatment initiation; patients who are not able to discontinue these drugs are considered ineligible
Treatment with drugs or herbal supplements known to be strong inhibitors/inducers of cytochrome P A or C within  weeks prior to Day 
Receiving treatment with medications that are known strong inhibitors or inducers of CYPA, and cannot be discontinued  days prior to the start of the treatment and during the course of the study.
Treatment with medications that are known to be strong inhibitors or inducers of CYP enzymes
Current treatment with medications or consuming foods that are strong inhibitors or inducers of CYPA/ or herbal medications and that cannot be discontinued at least one week prior to the start of treatment.
Treatment with inducers of cytochrome P A (CYPA) within  days prior to first dose of study treatment
Treatment with strong inducers or inhibitors (medications and herbal supplements) of cytochrome P A/ (CYPA/), or CYPA/ substrates with a QT prolongation risk that cannot be discontinued at least  half-lives (or if the half-life is unknown, days) prior to study drug treatment.
Patients receiving treatment with medications that are known to be strong inhibitors or inducers of CYPA/ or are metabolized by CYPB and CYPC, that have narrow therapeutic indices that cannot be discontinued at least  weeks before first dose of study treatment and for the duration of the study
Patients who have been exposed to medications, herbal preparations, or foods known to be predominant Cytochrome P C, C, D, A/ substrates, strong inhibitors or inducers within  days of planned first study treatment day
Unable or unwilling to discontinue use of strong inducers and inhibitors of CYP for at least  days prior to the first dose of study treatment and for the duration of the study; CYPA substrates can be administered, but investigators will need to be aware of possible increased or decreased effectiveness of the non-study drug and this should be recorded in concomitant medications; BCRP and PgP inducers and inhibitors should be used with caution if another alternative drug is not able to be used; Note: as this list is constantly evolving, if a medication is incorrectly documented as prohibited in this protocol, documentation from the site pharmacist to the contrary will be acceptable for the purposes of registration
Concomitant medications that are strong inhibitors of cytochrome P and CYPA up to  days before Cycle  Day  (pimozide, diltiazem, erythromycin, clarithromycin, and quinidine, and amiodarone up to  days before)
Further, patients treated with medications that were known to be strong inhibitors or inducers of CYPA/ that could not be discontinued at least a week prior to start of treatment with LDK and for the duration of the study were also excluded.
Patient is currently receiving any of the prohibited substances that cannot be discontinued  days prior to Cycle  Day : concomitant medications, herbal supplements, and/or fruits and their juices that are known as strong inhibitors or inducers of CYPA/; medications that have a narrow therapeutic window and are predominantly metabolized through CYPA/; systemic corticosteroids ?  weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment; concomitant medications with a known risk to prolong the QT interval and/or known to cause torsades de points that cannot be discontinued or replaced by safe alternative medication.
Receiving medications that meet one of the following criteria and that cannot be discontinued at least  week prior to the start of treatment with ceritinib and for the duration of participation:\r\n* Medication with a significant known risk of prolonging the QT interval or inducing torsades de pointes\r\n* Strong inhibitors or strong inducers of cytochrome P family , subfamily A, polypeptide / (CYPA/)\r\n* Therapeutic doses of warfarin sodium (Coumadin) or any other Coumadin-derived anti-coagulant; anticoagulants not derived from warfarin are allowed (e.g., dabigatran, rivaroxaban, apixaban)\r\n* Enzyme-inducing anticonvulsive agents\r\n* Herbal supplements
Treatment with medications that are known to be strong inhibitors or inducers of CYP enzymes
Use of concomitant medications that are known to be strong inhibitors or inducers of CYPA enzyme unless participant can discontinue or switch medications.
Treatment with strong cytochrome PA (CYPA) inducers within  days before the first dose of pevonedistat. Participants must have no history of amiodarone use within  months before the first dose of pevonedistat nor require the use of these medications during the study.
Patients actively receiving therapy with strong CYPA inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. See Appendix  for a list of these medications. This list may not be exhaustive.
Patients actively receiving therapy with herbal medicines that are strong CYPA inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug. These herbal medicines may include Echinacea, (including E. purpurea, E. angustifolia and E. pallida), Piperine, Artemisinin, St. John's Wort, and Ginkgo.